Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Active, not recruiting · NCT03580928 · Registry updated 2026-02-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-02-13 | NCT03580928 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Dana-Farber Cancer Institute | 324 |
| Genentech, Inc. | 221 |
| National Cancer Institute (NCI) | 3015 |
| National Institutes of Health (NIH) | 667 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Lifespan Cancer Institute | Providence | United States | 13 |
| Stamford Hospital/Bennett Cancer Center | Stamford | United States | 44 |